LEVON RESOURCES Forum: Community User: Summer.76

Brii Biosciences and VBI Vaccines Present Positive Data from Completed Phase 1b/2a Study on BRII-179 (VBI-2601) in Patients with Chronic Hepatitis B at the International Liver Congress 2021 https://www.businesswire.com/news/home/20210623005338/en/Brii-Biosciences-and-VBI-Vaccines-Present-Positive-Data-from-Completed-Phase-1b2a-Study-on-BRII-179-VBI-2601-in-Patients-with-Chronic-Hepatitis-B-at-the-International-Liver-Congress-2021 Data demonstrate that BRII-179 (VBI-2601) induced both B cell (antibody) and T cell responses in chronically-infected hepatitis B (HBV) patients, and was well-tolerated with no safety signals observed Results support further clinical evaluation of BRII-179 (VBI-2601) as an immunomodulator in combination with other treatment modalities as a potential functional cure for chronic HBV infection Abstract selected for inclusion in the ‘Best of ILC’ slide deck at EASL 2021 ...

👌😉

Irgendjemand muss ja was posten, sonst geht der channel ja noch unter 😉

Danke dir für die ganzen Infos 👍

https://www.businesswire.com/news/home/20210609005934/en/

Geht ja doch mal was :)

https://www.businesswire.com/news/home/20210609005241/en/

Wow, nichtmal fast track bewegt das hier 🤦🏻‍♂️🤦🏻‍♂️🤦🏻‍♂️

Geiiiiil 😍😍

https://finance.yahoo.com/news/vbi-vaccines-granted-fda-fast-120000648.html

https://seekingalpha.com/news/3698639-vbi-vaccines-vbi-1901-significantly-improves-12-month-overall-survival-in-gbm

Ja, war die aktuelle Pressemitteilung dazu

Wow tolle ergebnisse, aber die waren doch schon bekannt? 🤔

VBI Vaccines Announces Publication of Results from Pivotal Phase 3 Study, PROTECT, of VBI’s Prophylactic 3-Antigen Hepatitis B Vaccine Candidate in The Lancet Infectious Diseases https://finance.yahoo.com/news/vbi-vaccines-announces-publication-results-120000832.html

VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today announced that two abstracts highlighting data from the pivotal Phase 3 program evaluating the Company's 3-antigen prophylactic hepatitis B (HBV) vaccine candidate have been accepted for oral and poster presentation at the Canadian Liver Meeting 2021, taking place virtually May 2-5

https://www.stocktitan.net/news/VBIV/vbi-vaccines-announces-multiple-presentations-at-the-canadian-liver-0dj3wx8xxqmd.html 2 präsentationen diese woche